FDA May Limit Requests For Antiretroviral Drug Studies In Neonates
FDA is considering limiting its requests for antiretroviral drug studies in HIV-infected and HIV-exposed neonates
You may also be interested in...
Gilead's Viread pediatric studies should proceed despite a potential risk of bone toxicity, FDA told the Antiviral Drugs Advisory Committee during its Oct. 3 review of the HIV treatment.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials